28.08.2020 13:58:03
|
IBio And Planet Biotech Reach License Agreement For Development Of COVID-19 Therapeutic
(RTTNews) - Shares of iBio Inc. (IBIO) were gaining 14 percent in pre-market trading on Friday, after the company said it has reached an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc.
As per the terms of the deal, iBio obtained an exclusive license to Planet's ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.
In the pre-market trading, IBIO was trading at $2.42 up $0.31 or 14.69 percent.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu iBio Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |